Effects of Acetazolamide on intracranial pressure in glaucoma

Effects of Acetazolamide on intracranial pressure in glaucoma - Acetazolamide and Glaucoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48559

Enrollment

Registered

2018-06-14

Start date

2019-05-22

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: *50-70 years of age *Presence of DPOAEs in at least one ear *Written informed consent. *For patients only: taking acetazolamide as part of their regular IOP-lowering medication

Exclusion criteria

Exclusion criteria: *No presence of DPOAEs *Any other medications that may influence ICP *For healthy controls, glaucoma or family history of glaucoma. This will be determined by form F1a and the ophthalmologic screening described in section 3.

Design outcomes

Primary

Measure	Time frame
Peak and trough values of ICP (phase shifts of DPOAEs) and IOP for patients and controls, for patients measured before and after taking their acetazolamide.	—

Countries

Netherlands

Outcome results